Skip to Content

Generic Synalgos-DC Availability

Synalgos-DC is a brand name of aspirin/caffeine/dihydrocodeine, approved by the FDA in the following formulation(s):

SYNALGOS-DC (aspirin; caffeine; dihydrocodeine bitartrate - capsule;oral)

  • Manufacturer: CARACO
    Approval date: September 6, 1983
    Strength(s): 356.4MG;30MG;16MG [RLD]

Has a generic version of Synalgos-DC been approved?

An Authorized Generic version of Synalgos-DC has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance, and unlike a generic, the Authorized Generic has exactly the same inactive ingredients.

List of authorized generic versions:

  • Aspirin, Caffeine, and Dihydrocodeine Bitartrate ORAL CAPSULE 356.4; 30; 16 mg/1; mg/1; mg
    Caraco Pharmaceutical Laboratories, Ltd
    NDC Code: 576640419

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Synalgos-DC. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide